You are here

Our People

We work with leading research scientists to identify and nurture research that has strong clinical and commercial potential. Projects with translational potential are guided through the process by one of our experienced Business Development Managers. We build strong personal relationships with our partners and keep lines of communication open and simple to ensure the free flow of information and ideas. This ensures all potential opportunities are capitalised on as innovatively and efficiently as possible.

Cancer Research Technology Board Open

Peter Chambré, Chairman Peter has been Chairman of CRT since October 2011. He is also Chair of Immatics N.V., a company developing new cancer immunotherapy treatments, and is a director of UDG Healthcare plc. He has been a director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in July 2006. Peter has been a CRUK Trustee since 2016.


 

Dr Andy Richards CBE Andy is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Arecor Ltd, Abcodia Ltd, Closed Loop Medicine Ltd, Ieso Digital Health Ltd, and Congenica Ltd, as well as being a director of Owlstone Medical Ltd. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT in August 2003, is a member of CRUK and on the investment committee of the CRUK Seed Fund. He is a graduate of Cambridge University with a PhD in Chemistry.


Iain Foulkes, PhD Iain is Cancer Research UK's Executive Director of Research and Innovation and CEO of Cancer Research Technology. Iain is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute. He then became a science writer and medical journalist, before moving into Policy and Communications at the Imperial Cancer Research Fund (ICRF). During his time at ICRF, he worked closely with Sir Paul Nurse, who at that time was Chief Executive, helping to drive through the merger of ICRF and Cancer Research Campaign to become Cancer Research UK. From January 2003, he was Director of Strategic Development in Fundraising and Supporter Marketing, and has supported the early-stage development of UK Centre for Medical Research and Innovation working with Sir Paul Nurse.


Deborah Harland Debbie was appointed to the board of CRT in 2015. She is a Venture Partner in the London office of SR One and focuses on the discovery and development of novel medicines and therapeutic platforms. Debbie established the European operations of the fund in 2005 bringing over 17 years of experience from her accomplished career across a number of operational roles in the pharmaceutical industry. Leveraging her experience in clinical development, business development and licensing, Debbie has a track record of identifying, supporting and growing successful biotech companies. She is a respected and high profile member of the venture community in Europe with a wide ranging network to source, evaluate and shape innovative investments for SR One across multiple geographies. In addition to her Board roles with SR One portfolio companies, Debbie is a member of the Advisory Board of the University of Cambridge Maxwell Centre’s ‘Impulse’ program for young entrepreneurs.


Andrew Waldron (Company Secretary)


Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.


Parker Moss Parker is a member of the Secretary of State for Health's technology advisory board.  He is currently Chief Commercial & Partnerships Officer at Genomics England.  Previously Parker was Entrepreneur in Residence at the Biotech and Technology venture funds backed by Fidelity, F-Prime and Eight Roads.  He led an investment and was placed for a year into Owkin, a machine learning startup that supports academic and pharmaceutical research in tumour evolution and heterogeneity in cancer. Parker also worked in technology leadership roles in the NHS.

Therapeutic Discovery Laboratories Open

Opportunity Sourcing, Business Development & Alliance Management Open

 

Dr Phil Masterson, Associate Director.  Phil has been working as Associate Director of the Commercial Partnerships team since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


Julie Little, Associate Director Strategic AlliancesJulie Little, Associate Director Strategic Alliances. Julie obtained her first degree in Biological Sciences from Exeter University and her MSc in Molecular Biology and Biotechnology from University College London, which involved a placement at Unilever’s research laboratory in Bedfordshire. This led to a career at Unilever for over 16 years, during which time she gained an MPhil and worked on diverse discovery research projects focused on personal care products. Julie was a member of the antibody technology team using phage display technology to isolate antibodies, including nanobodies, to a wide range of targets from food stains to damaged hair. Julie then moved to Genzyme Therapeutics Limited to help establish a new research facility in Cambridge focused on antibody generation and discovery research. There she led the phage display team and worked on projects across a range of disease indications including the development of anti-idiotype antibodies to support clinical development for the multiple sclerosis drug, Lemtrada. In 2012, Julie joined Cancer Research Technology, the predecessor of CRUK’s Commercial Partnerships team, as a Business Development Manager and in January 2021 was promoted to Associate Director.

Read more about our services

USA Office Open

 Andrea Schievella, President of our US Office Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since joining the organisation she has been building relationships between CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to this role, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  


Dr Robert Bondaryk, Global Head of Ximbio the non-profit bioresearch reagents unit of Cancer Research UK. Bob brings extensive commercial experience from previous roles as Chief Executive Officer of Kerafast, Inc., Senior Vice President and General Manager of Cogenics, a pharmacogenomics division of Clinical Data, Inc., General Manager and Senior Vice President at Proteome Systems, Inc., the US unit of an Australian proteomics company. Vice President Life Sciences and Drug Discovery at Fisher Scientific, managing the Life Sciences and Chemicals product portfolio. Bob was the Co-Founder and President of LifeTech/MedTech Capital, a life sciences investment banking boutique, overseeing mergers, acquisitions and corporate partnerships. He began his business career at Arthur D. Little, Inc. as Senior Management Consultant in biotechnology after receiving his BA in biology and psychology from Bowdoin College and his PhD from Harvard University in biochemistry.

 

View our projects

Clinical Partnerships Open

Research tools - Ximbio Open

Dr Robert Bondaryk, Global Head of Ximbio the non-profit bioresearch reagents unit of Cancer Research UK. Bob brings extensive commercial experience from previous roles as Chief Executive Officer of Kerafast, Inc., Senior Vice President and General Manager of Cogenics, a pharmacogenomics division of Clinical Data, Inc., General Manager and Senior Vice President at Proteome Systems, Inc., the US unit of an Australian proteomics company. Vice President Life Sciences and Drug Discovery at Fisher Scientific, managing the Life Sciences and Chemicals product portfolio. Bob was the Co-Founder and President of LifeTech/MedTech Capital, a life sciences investment banking boutique, overseeing mergers, acquisitions and corporate partnerships. He began his business career at Arthur D. Little, Inc. as Senior Management Consultant in biotechnology after receiving his BA in biology and psychology from Bowdoin College and his PhD from Harvard University in biochemistry.

 

Read more about research tools

Chief Business Officer Open

Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.

  • Peter Chambré, Chairman Peter has been Chairman of CRT since October 2011. He is also Chair of Immatics N.V., a company developing new cancer immunotherapy treatments, and is a director of UDG Healthcare plc. He has been a director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in July 2006. Peter has been a CRUK Trustee since 2016.


     

    Dr Andy Richards CBE Andy is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Arecor Ltd, Abcodia Ltd, Closed Loop Medicine Ltd, Ieso Digital Health Ltd, and Congenica Ltd, as well as being a director of Owlstone Medical Ltd. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT in August 2003, is a member of CRUK and on the investment committee of the CRUK Seed Fund. He is a graduate of Cambridge University with a PhD in Chemistry.


    Iain Foulkes, PhD Iain is Cancer Research UK's Executive Director of Research and Innovation and CEO of Cancer Research Technology. Iain is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute. He then became a science writer and medical journalist, before moving into Policy and Communications at the Imperial Cancer Research Fund (ICRF). During his time at ICRF, he worked closely with Sir Paul Nurse, who at that time was Chief Executive, helping to drive through the merger of ICRF and Cancer Research Campaign to become Cancer Research UK. From January 2003, he was Director of Strategic Development in Fundraising and Supporter Marketing, and has supported the early-stage development of UK Centre for Medical Research and Innovation working with Sir Paul Nurse.


    Deborah Harland Debbie was appointed to the board of CRT in 2015. She is a Venture Partner in the London office of SR One and focuses on the discovery and development of novel medicines and therapeutic platforms. Debbie established the European operations of the fund in 2005 bringing over 17 years of experience from her accomplished career across a number of operational roles in the pharmaceutical industry. Leveraging her experience in clinical development, business development and licensing, Debbie has a track record of identifying, supporting and growing successful biotech companies. She is a respected and high profile member of the venture community in Europe with a wide ranging network to source, evaluate and shape innovative investments for SR One across multiple geographies. In addition to her Board roles with SR One portfolio companies, Debbie is a member of the Advisory Board of the University of Cambridge Maxwell Centre’s ‘Impulse’ program for young entrepreneurs.


    Andrew Waldron (Company Secretary)


    Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.


    Parker Moss Parker is a member of the Secretary of State for Health's technology advisory board.  He is currently Chief Commercial & Partnerships Officer at Genomics England.  Previously Parker was Entrepreneur in Residence at the Biotech and Technology venture funds backed by Fidelity, F-Prime and Eight Roads.  He led an investment and was placed for a year into Owkin, a machine learning startup that supports academic and pharmaceutical research in tumour evolution and heterogeneity in cancer. Parker also worked in technology leadership roles in the NHS.

  •  

    Dr Phil Masterson, Associate Director.  Phil has been working as Associate Director of the Commercial Partnerships team since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


    Julie Little, Associate Director Strategic AlliancesJulie Little, Associate Director Strategic Alliances. Julie obtained her first degree in Biological Sciences from Exeter University and her MSc in Molecular Biology and Biotechnology from University College London, which involved a placement at Unilever’s research laboratory in Bedfordshire. This led to a career at Unilever for over 16 years, during which time she gained an MPhil and worked on diverse discovery research projects focused on personal care products. Julie was a member of the antibody technology team using phage display technology to isolate antibodies, including nanobodies, to a wide range of targets from food stains to damaged hair. Julie then moved to Genzyme Therapeutics Limited to help establish a new research facility in Cambridge focused on antibody generation and discovery research. There she led the phage display team and worked on projects across a range of disease indications including the development of anti-idiotype antibodies to support clinical development for the multiple sclerosis drug, Lemtrada. In 2012, Julie joined Cancer Research Technology, the predecessor of CRUK’s Commercial Partnerships team, as a Business Development Manager and in January 2021 was promoted to Associate Director.

    Read more about our services

  •  Andrea Schievella, President of our US Office Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since joining the organisation she has been building relationships between CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to this role, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  


    Dr Robert Bondaryk, Global Head of Ximbio the non-profit bioresearch reagents unit of Cancer Research UK. Bob brings extensive commercial experience from previous roles as Chief Executive Officer of Kerafast, Inc., Senior Vice President and General Manager of Cogenics, a pharmacogenomics division of Clinical Data, Inc., General Manager and Senior Vice President at Proteome Systems, Inc., the US unit of an Australian proteomics company. Vice President Life Sciences and Drug Discovery at Fisher Scientific, managing the Life Sciences and Chemicals product portfolio. Bob was the Co-Founder and President of LifeTech/MedTech Capital, a life sciences investment banking boutique, overseeing mergers, acquisitions and corporate partnerships. He began his business career at Arthur D. Little, Inc. as Senior Management Consultant in biotechnology after receiving his BA in biology and psychology from Bowdoin College and his PhD from Harvard University in biochemistry.

     

    View our projects

  • Dr Robert Bondaryk, Global Head of Ximbio the non-profit bioresearch reagents unit of Cancer Research UK. Bob brings extensive commercial experience from previous roles as Chief Executive Officer of Kerafast, Inc., Senior Vice President and General Manager of Cogenics, a pharmacogenomics division of Clinical Data, Inc., General Manager and Senior Vice President at Proteome Systems, Inc., the US unit of an Australian proteomics company. Vice President Life Sciences and Drug Discovery at Fisher Scientific, managing the Life Sciences and Chemicals product portfolio. Bob was the Co-Founder and President of LifeTech/MedTech Capital, a life sciences investment banking boutique, overseeing mergers, acquisitions and corporate partnerships. He began his business career at Arthur D. Little, Inc. as Senior Management Consultant in biotechnology after receiving his BA in biology and psychology from Bowdoin College and his PhD from Harvard University in biochemistry.

     

    Read more about research tools

  • Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.